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BACKGROUND 
Obesity not only increases breast cancer risk but also reduces chemotherapy efficacy.1, 
2 The pathological complete response (pCR) and disease-free survival rates after 
neoadjuvant chemotherapy (NAC) tend to be lower among obese patients.1, 3 Thus, 
understanding the mechanisms by which obesity negatively affects chemotherapy 
outcomes is essential in improving the prognosis of obese breast cancer patients. The 
World Health Organization (WHO) defines obesity as a body mass index (BMI) >25 
kg/m2. BMI is a simple and reliable surrogate measure of obesity; however, this index is 
not a substitute for actual body fat distribution (BFD), as it is based only on weight and 
height. 
Body fat is generally distributed viscerally, subcutaneously, and internally (mostly in 
the liver), and the BFD pattern differs between individuals.4, 5 Furthermore, the endocrine 
function of fat cells differs according to the anatomical site. For example, dysfunctional 
visceral fat cells promote tumor progression by increasing inflammatory cytokines 
(interleukin-6 and tumor necrosis factor-α) and endocrine products (aromatase and 
adiponectin) through activation of the phosphatidylinositol-3 kinase/Akt pathway.6 On 
the other hand, excess fat accumulation in the liver (i.e., fatty liver) worsens insulin 
resistance and promotes tumor cell proliferation and survival by activating the insulin-
like growth factor pathway.7 Given these facts, individual patient BFD is an important 
consideration in obesity research. Changes in body composition are known to reduce 
NAC efficacy in the clinical setting. However, to date, only a few studies have 
investigated the association between BFD and chemotherapeutic efficacy.8, 9 
Therefore, in this study, we aimed to clarify the effect of actual BFD on NAC outcomes 
in breast cancer patients. 
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MATERIALS AND METHODS 
Inclusion Criteria 
One hundred seventy-two advanced breast cancer patients who underwent surgery after 
NAC between January 2004 and December 2012 were included in the present study. The 
inclusion criteria were as follows: Eastern Cooperative Oncology Group performance 
status of 0−1, a clinical T2 classification or higher (tumor size ≥20 mm) based on the 
American Joint Committee on Cancer/Union for International Cancer Control TNM 
classification,10 and a positive axillary lymph node proven by fine needle aspiration 
cytology. Core needle biopsy specimens were obtained from all patients before NAC, and 
were analyzed immunohistochemically for histological type, grade, and subtype. Patients 
with distant metastasis, identified based on computed tomography (CT) and 
99mtechnetium bone scans performed before NAC, were excluded from the study.  
The study protocol was approved by our institutional ethics committee and conducted 
in accordance with the Declaration of Helsinki. Informed consent was obtained from each 
patient. 
 
Evaluation of Body Fat Distribution 
The WHO classification was used to categorize patients into four weight groups 
according to BMI: underweight (BMI <18.5 kg/m2), normal (BMI ≥18.5 and <25 kg/m2), 
overweight (BMI ≥25 and <30 kg/m2), and obese (BMI ≥30 kg/m2). CT scans taken at 
the time of initial treatment were analyzed for actual BFD using a CT image analyzer 
(CYNAPSE VINCENT®, Fujifilm Co. Ltd., Tokyo, Japan). The subcutaneous fat area 
(SFA, [cm2]) and visceral fat area (VFA [cm2]) were calculated using axial cross-sectional 
CT images taken at the navel level and used to estimate subcutaneous and visceral fat 
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mass. In addition to SFA and VFA, the degree of muscle mass, a major component of 
body composition, was analyzed. The lumbar muscle cross-sectional area (LMCA [m2]) 
was used as a measure of total body skeletal muscle mass and was quantified by CT 
analysis at the third lumbar vertebrae level (L3) with a Hounsfield unit threshold range 
of –29 to +150.11 The LMCA included the psoas, paraspinal muscles (erector spinae, 
quadratus lumborum), and abdominal wall muscles (transversus abdominus, external and 
internal obliques, and rectus abdominus). To adjust the total L3 skeletal muscle mass 
according to patient stature, the lumbar skeletal muscle index (LSMI) was used. To 
calculate the LSMI, the LMCA was normalized to the body surface area, which is linearly 
related to the total body muscle mass (LSMI = total L3 skeletal muscle mass/body surface 
area [cm²/m²]).12 Fat accumulation in the liver was used as a measure of internal fat 
distribution. The CT liver-to-spleen attenuation ratio (liver/spleen [L/S] ratio) was used 
for evaluation of fatty liver. Fatty liver was defined as an L/S ratio of >1.0.13 
 
Neoadjuvant Chemotherapy Regimen and Dosing 
The NAC regimen consisted of an anthracycline followed by a taxane in accordance 
with the results of major clinical trials.14 Patients with human epidermal growth factor 
receptor 2 (HER2)-expressing tumors were administered trastuzumab for 1 year.15, 16 The 
chemotherapy dose was based on the actual weight, regardless of the patient’s body 
composition. Adverse events that occurred during NAC were evaluated according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 
and recorded. The dose intensity and relative dose intensity (RDI) were calculated using 
electronically recorded data. The dose intensity (mg/m2/week) was calculated using the 
following formula: total dose (mg/m2)/duration of administration (weeks). RDI was 
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calculated as follows: (dose intensity/planned dose intensity) × 100.  
 
Pathological Evaluation 
All histopathological evaluations were performed by board-certified pathologists. The 
definition of pCR has not yet been established, and several definitions based on residual 
tumor status in the axillary lymph nodes and local tumor site exist.17 In the present study, 
we used the following two definitions for pCR: no residual tumor cells in the breast 
(ypT0) and noninvasive residuals allowed in the intraductal components (ypTis/mic), 
regardless of the axillary lymph node status (ypN+).18, 19 
 
Statistical Methods 
The present study was designed as a retrospective patient control study. Pearson’s 
correlation test was used to analyze the correlation between BFD parameters and BMI (n 
= 172). Changes in BFD parameters after menopause were analyzed using Student’s t-
test (n = 172). As previous studies did not identify definitive cut-off values for VFA and 
SFA, we instead used a cut-off value of 100 cm2 for both parameters based on the 
Guideline for Screening Metabolic Disease created by the Japan Society for the Study of 
Obesity.20 The guideline CT-based cut-off values were generated based on morbidity risks 
in 1,193 patients.20 As dual-energy X-ray absorptiometry was not performed, CT analysis 
was also used to measure skeletal muscle mass. Sarcopenia was defined as a skeletal 
muscle mass of at least 2 standard deviations lower than that of the normal population.21 
Using this definition, the present study included only five sarcopenic patients. Therefore, 
we alternatively used the term “reduced muscle mass,” which was defined as an LSMI 
less than or equal to the lower quartile for all patients.  
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Kaplan-Meier survival analysis was performed to evaluate the effect of BFD 
parameters on survival outcomes (n = 172). Distant disease-free survival (DDFS) was 
defined as the time from initial NAC treatment to relapse at any distant site. Multivariate 
analysis by Cox proportional hazards regression model was used to determine the 
associations of BMI, BFD parameters, and clinicopathological factors with DDFS and 
overall survival (n = 172). Hazard ratios (HRs) and their 95% confidence intervals (CIs) 
were also calculated. All statistical analyses were performed using SPSS Statistics® 
version 23 (IBM Co. Ltd., Tokyo, Japan). A p value of < 0.05 was considered significant, 
and all statistical tests were two-sided. 
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RESULTS 
Patient Characteristics 
The average BMI was 22.9 kg/m2. According to the WHO classification, 111 (65%), 
18 (10%), 35 (20%), and 8 (5%) patients were normal weight, underweight, overweight, 
and obese, respectively. We determined the distribution of breast cancer subtypes to 
evaluate the selection bias. The subtypes were as follows: estrogen receptor (ER)-positive 
(+)/HER2-negative (-) in 45% of patients; ER+/HER2+ in 17% of patients; ER-/HER2+ 
in 20% of patients; and triple-negative in 18% of patients (Table 1). This distribution of 
breast cancer subtypes is similar to that in previous studies,22, 23 suggesting that selection 
bias was minimal in our study. 
 
Body Fat Distribution 
In the BFD analysis, the average SFA was 138.2 cm2 and the median VFA was 73.0 
cm2. To further evaluate BFD, we calculated the VFA/SFA ratio. Although the SFA was 
much higher than the VFA, the median VFA/SFA ratio was 52%, indicating an almost 
equal visceral and subcutaneous fat distribution. The median L/S ratio was 1.3, and 18 
patients had fatty liver. Table 2 shows the results of the correlation analyses between the 
BMI and BFD parameters. BMI significantly correlated with the SFA, VFA, VFA/SFA 
ratio, and L/S ratio (r = 0.72, 0.62, 0.27, and -0.45, respectively; all p <0.05). In contrast, 
muscle mass (LSMI) did not significantly correlate with BMI (p = 0.19; Table 2).  
Next, we analyzed the changes in body composition between pre- and post-menopausal 
women. The SFA and VFA increased significantly, whereas the LSMI decreased 
significantly after menopause (all p <0.05). In addition, the VFA/SFA ratio increased 
significantly after menopause, indicating that the amount of visceral fat exceeded that of 
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subcutaneous fat (p <0.05). In contrast, the BMI and L/S ratio were not influenced by the 
menopausal status. These results indicate that menopause causes marked changes in body 
composition, including reduced muscle mass and increased visceral fat. 
 
Body Fat Distribution and Pathological Complete Response 
Of the 172 patients, 46 achieved pCR. The pCR rates for patients with ER+/HER2-, 
ER+/HER2+, ER-/HER2+, and triple-negative subtypes were 12% (9/77), 30% (9/30), 
50% (17/34), and 35% (11/31), respectively. Table 3 shows the results of the univariate 
analysis of the association of pCR with BMI, BFD parameters, and clinicopathological 
factors. No significant relationship was observed between pCR and BMI (chi-square test; 
p = 0.88). Moreover, the BFD parameters were not associated with pCR. Among the 
clinicopathological factors, the histological type and subtype were significantly 
associated with pCR (p <0.05; Table 3). 
 
Adverse Events and Relative Dose Intensity 
Twenty-eight patients experienced grade 3 hematological adverse events, of which 
neutropenia was the most common. The normal weight group had the highest rate of grade 
3 adverse events, at 17.1% (19/111). However, in the univariate analysis, BMI was not 
associated with the occurrence of adverse events (p <0.05; Table 4). The RDI did not 
differ significantly between BMI groups and was over 98% in all groups (p = 0.19; Table 
4). 
 
Body Fat Distribution and Survival 
The median follow-up time was 1638 days. DDFS curves stratified by BMI and BFD 
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parameters are shown in Figure 1a-d. The DDFS did not differ significantly according to 
the BMI group. Furthermore, no significant difference in DDFS was observed when the 
overweight and obese groups were combined (log-rank test; p = 0.88). 
The DDFS was significantly worse for the high VFA group (VFA ≥100 cm2) compared 
with the low VFA group (VFA <100 cm2; log-rank test; p <0.05, HR: 2.36, 95% CI: 
1.27−4.38). In contrast, the DDFS did not differ significantly according to the SFA, 
LSMI, or L/S (data not shown).  
We further performed an exploratory analysis to determine the impact of menopausal 
status on the relationship between VFA and DDFS. DDFS did not differ significantly 
between patients with low or high VFA in the premenopausal group (log-rank test: p = 
0.082; Figure 2a). However, in the postmenopausal group, the DDFS was significantly 
worse in patients with a high VFA compared to those with a low VFA (log-rank test: p 
<0.05, HR: 2.79, 95% CI: 1.29−6.05; Figure 2b). Furthermore, multivariate analysis 
revealed that VFA was an independent prognostic factor for DDFS (p <0.05, HR: 2.42, 
95% CI: 1.28−4.57; Table 5). The subtype and pCR were also independent prognostic 
factors for DDFS. Overall survival analysis according to BMI and BFD parameters was 
also performed, although no significant differences were observed (data not shown). 
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DISCUSSION 
Despite the numerous studies regarding body composition and treatment outcomes, 
only a few studies have analyzed the association between body composition and NAC 
outcomes.8, 24 Our study has two important findings. First, the dominant change in BFD 
after menopause is increased visceral fat accumulation. This increase occurs regardless 
of BMI. Second, visceral fat accumulation was strongly associated with survival after 
NAC, especially in postmenopausal breast cancer patients. 
In the present study, we found that menopause causes characteristic changes in BFD, 
including increased VFA and decreased skeletal muscle mass, and these changes are not 
reflected in the BMI value. The menopause-related changes in body composition in our 
study are consistent with those reported in previous studies.25, 26 However, the lack of 
effect of menopause on liver fat accumulation was unexpected, given the increase in the 
other BFD parameters. Only 18 patients in our study had fatty liver, suggesting that the 
incidence of non-alcoholic fatty liver disease in obese patients may be lower than 
expected. In a systematic review, the mean morbidity rate for non-alcoholic fatty liver 
disease among obese patients was reported to be 33%.5 Confounding factors make it 
difficult to determine whether fatty liver or visceral fat worsen prognosis. However, our 
findings suggest that visceral fat accumulation has a significant negative effect on breast 
cancer prognosis. 
Recently, the relationship between sarcopenic obesity and cancer mortality has become 
a major area of interest in the cancer nutrition field. Sarcopenic obesity, defined as a 
combination of excess weight and reduced muscle mass, leads to poor prognosis by 
lowering functional status and increasing chemotherapy-related morbidity and toxicity.12 
Only a few patients had sarcopenia or sarcopenic obesity in the present study, and muscle 
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depletion had no significant effect on survival outcome. The result may came from the 
fact that present threshold value for LSMI was higher than previous studies, ranging from 
38.5 to 41.0 cm²/m² according to the optimal stratification, hence the distribution may be 
inappropriate for evaluating the effect of sarcopenia on survival.12, 27, 28 However, patients 
with pre-sarcopenia may have a higher risk of worsening unfavorable body composition 
changes after chemotherapy or endocrine therapy. Although we only evaluated body 
composition at the time of the initial treatment in the present study, changes in body 
composition also need to be monitored during the follow-up period to prevent sarcopenic 
obesity. 
In the present study, we demonstrated that patients with a high amount of visceral fat 
had a significantly shorter DDFS, even though VFA was not associated with 
chemosensitivity (i.e., the pCR rate). When determining the effect of obesity on NAC 
outcomes, both the chemosensitivity to NAC (pCR rate) and survival after NAC must be 
considered. The largest study (n = 1,169) investigating the relationship between NAC 
chemosensitivity and obesity in breast cancer was conducted at the MD Anderson Cancer 
Center in 2008. In this study, the pCR rate was significantly lower in overweight/obese 
patients (BMI ≥25 kg/m2) than in normal/underweight patients (BMI <25 kg/m2).1 In 
contrast, a meta-analysis of eight major clinical trials found no significant association 
between obesity and chemosensitivity to NAC.29 Thus, the impact of obesity on NAC 
chemosensitivity remains controversial. On the other hand, studies have consistently 
shown that obese patients have a significantly worse survival outcome after NAC.1, 3, 29, 
30 Together, these studies indicate that obesity has a greater impact on survival outcomes 
after NAC than NAC chemosensitivity. Obesity promotes cancer progression by 
increasing cell proliferation, cell survival, invasion/metastasis, and angiogenesis. These 
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effects are mediated by the induction of insulin resistance and inflammation, and 
increases in leptin, adiponectin, plasminogen activator inhibitor-1, and vascular 
endothelial growth factor levels.6 In particular, visceral fat, which is more hormonally 
active than other types of body fat, strongly promotes these effects.6, 31 Thus, the shorter 
DDFS in the high visceral fat group in our study may be due to the positive effect of 
visceral fat on cancer progression. 
 
CONCLUSION 
To date, much attention has been paid to increasing the pCR rate after NAC, whereas 
little emphasis has been placed on supportive care during the NAC follow-up period. 
However, a recent study demonstrated the importance of supportive care, including 
nutritional support and physical exercise, for improving breast cancer survival.32 Thus, a 
multidisciplinary approach including nutritional support and physical exercise is needed 
to improve survival outcomes after NAC in obese breast cancer patients. 
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